Use of gene therapy to induce antigen-specific immunologic unresponsiveness to class I xenogeneic major histocompatibility complex antigens.
Schumacher
I
I
Department of Surgery, University of Nebraska Medical Center, Omaha 68198-3280.
Jeevarathnam
S
S
Rubbocki
R
R
Fox
I J
IJ
D000818:Animals; D015478:Antigens, Heterophile / Q000276:immunology*; D001483:Base Sequence; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002460:Cell Line; D017931:DNA Primers; D015316:Genetic Therapy; D005822:Genetic Vectors; D015789:HLA-A2 Antigen / Q000096:biosynthesis / Q000276:immunology; D015793:HLA-B7 Antigen / Q000096:biosynthesis / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D007114:Immunization; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D012190:Retroviridae; D014162:Transfection; D014183:Transplantation, Heterologous / Q000276:immunology
D015478:Antigens, Heterophile; D017931:DNA Primers; D015789:HLA-A2 Antigen; D015793:HLA-B7 Antigen; D015395:Histocompatibility Antigens Class I